Trial
NCT04899271
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dompé Farmaceutici S.p.A
Collaborators
—
Condition
New-onset Type 1 Diabetes
Intervention
Ladarixin
Why stopped
low recruitment rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-14